SHANGHAI and PRINCETON, NJ, April 07, 2022 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, announced today today the appointment of Wei Wei Chen for the company’s Board of Directors.
“I am delighted to welcome Wei Wei Chen to LianBio’s Board of Directors,” said Yizhe Wang, Ph.D., Chairman and CEO of LianBio. “His in-depth knowledge of the Chinese market, combined with his ability to manage business growth and transformation, will be extremely beneficial to LianBio as we grow our team and progress towards advancing our diverse portfolio of potentially transformative medicines for patients in China and throughout Asia. .”
Ms. Chen brings over 17 years of experience as a CFO for a number of companies, including in the retail and healthcare sectors. Most recently, she served as Vice President, Chief Financial Officer of Starbucks (China) Company Limited, where she drove significant business growth and played a key role in multiple business transformation initiatives. Prior to that, Ms. Chen served as CFO of Yum! China Division of Brands, Inc. Prior to joining the retail industry, Ms. Chen worked in the healthcare industry for fifteen years, where she last served as Chief Financial Officer, Asia of Sanofi Group . Prior to Sanofi, she worked for Schering-Plough Corporation. Ms. Chen began her career as an auditor with Ernst & Young, LLP. She is currently a Non-Executive Director at DFI Retail Group and a Non-Executive Director at HBM Holding Limited. Ms. Chen is a certified public accountant. She earned her bachelor’s degree in accounting from the University of Illinois at Urbana-Champaign and her master’s degree in business administration from Rutgers University.
“I am honored to join LianBio’s Board of Directors and excited to have the opportunity to contribute to the company’s mission of providing medicines to patients with significant unmet medical needs,” said Ms Chen. “I look forward to supporting LianBio’s management team to continue to develop the next generation of innovative therapies in Greater China and throughout Asia.”
LianBio is a cross-border biotechnology company whose mission is to bring transformative medicines to historically underserved patients in China and other Asian markets. Through partnerships with highly innovative biopharmaceutical companies around the world, LianBio is developing a diverse portfolio of clinically validated product candidates with the potential to set new standards of care in the cardiovascular, oncology, ophthalmology, inflammatory and respiratory fields. LianBio is building an international infrastructure to position the company as a partner of choice with a platform to access China and other Asian markets. For more information, visit www.lianbio.com.
For investor inquiries, please contact:
For media inquiries, please contact:
Katherine Smith, CanaleComm
Email: [email protected]
Phone. : +1 619 849 5378